Sound Income Strategies LLC Invests $60,000 in Hologic, Inc. (NASDAQ:HOLX)

Sound Income Strategies LLC bought a new stake in Hologic, Inc. (NASDAQ:HOLX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 838 shares of the medical equipment provider’s stock, valued at approximately $60,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of HOLX. Wolff Wiese Magana LLC acquired a new position in Hologic in the third quarter valued at $25,000. General Partner Inc. purchased a new position in shares of Hologic during the fourth quarter worth about $26,000. Groupama Asset Managment increased its position in Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 2,999 shares during the period. Sunbelt Securities Inc. purchased a new stake in Hologic during the 2nd quarter valued at approximately $37,000. Finally, First Horizon Advisors Inc. lifted its position in Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on HOLX. Wolfe Research assumed coverage on Hologic in a report on Friday, December 13th. They issued a “peer perform” rating on the stock. UBS Group lifted their target price on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Needham & Company LLC reiterated a “buy” rating and set a $90.00 price target on shares of Hologic in a research note on Monday, January 13th. BNP Paribas upgraded shares of Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Finally, Raymond James lifted their price objective on Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. Seven investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Hologic presently has a consensus rating of “Moderate Buy” and an average target price of $88.92.

Insider Activity at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.88% of the company’s stock.

Hologic Stock Up 0.5 %

Shares of NASDAQ HOLX opened at $71.02 on Friday. The firm’s 50-day moving average is $74.01 and its two-hundred day moving average is $78.25. The company has a market capitalization of $16.03 billion, a PE ratio of 21.33, a price-to-earnings-growth ratio of 2.43 and a beta of 0.97. Hologic, Inc. has a 12-month low of $68.61 and a 12-month high of $84.67. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03.

Hologic (NASDAQ:HOLX) last posted its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.01. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. Hologic’s revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.89 EPS. Equities analysts anticipate that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.